AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39683633 — intervention group
Group type: EXPERIMENTAL
Intervention: 630 mg A-GPC (HD)
Number of subjects: 20
Study 39683633 — intervention group
Group type: EXPERIMENTAL
Intervention: 315 mg A-GPC (LD)
Number of subjects: 20
Study 39683633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 39684514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma citrate levels in ESLD patients
Number of subjects: 129
Study 39684514 — intervention group
Group type: COMPARATOR
Intervention: Plasma citrate levels in PREVEND participants
Number of subjects: 129
Study 39684943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2022 cohort
Number of subjects: 833
Study 39684943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2023 cohort
Number of subjects: 833
Study 39684943 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model
Number of subjects: 833
Study 39685557 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative lung ultrasound findings
Number of subjects: 0
Study 39685557 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39686459 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to the affected shoulder and scapular regions
Number of subjects: 114
Study 39686459 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 114
Study 39686497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tui-Na (TN)
Number of subjects: 50
Study 39686497 — intervention group
Group type: COMPARATOR
Intervention: Positional Release Techniques (PRT)
Number of subjects: 50
Study 39686569 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOSTAR multielectrode radiofrequency balloon catheter
Number of subjects: 257
Study 39686614 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit blood pressure variability (BPV)
Number of subjects: 8034
Study 39686614 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in target range (TTR)
Number of subjects: 8034
Study 39686614 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit BPV
Number of subjects: 8034
Study 39686620 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab (up to 1200 mg every 4 weeks)
Number of subjects: 154
Study 39686647 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids alone or in combination with immunosuppressive drugs and/or IVIg
Number of subjects: 22
Study 39686647 — intervention group
Group type: EXPERIMENTAL
Intervention: Microstructural damage in the corpus callosum
Number of subjects: 22
Study 39686672 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein pulsatility index
Number of subjects: 145
Study 39686830 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol powder air polishing (EPAP) followed by subgingival instrumentation 1 month later
Number of subjects: 22
Study 39686830 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (control)
Number of subjects: 22
Study 39687049 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS to the right DLPFC and intermittent theta burst stimulation (iTBS) to the cerebellum, delivered sequentially in 20 sessions along with antipsychotics.
Number of subjects: 0
Study 39687049 — intervention group
Group type: COMPARATOR
Intervention: Sham condition along with antipsychotics.
Number of subjects: 0
Study 39687188 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Number of subjects: 115
Study 39687188 — intervention group
Group type: COMPARATOR
Intervention: No-ICG (Control)
Number of subjects: 115
Study 39687279 — intervention group
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation (tVNS)
Number of subjects: 30
Study 39687429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MOT-IVR intervention
Number of subjects: 10
Study 39687431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral maintenance therapy with trofosfamide (2 × 75 mg/m²), etoposide, and idarubicin for 25 weeks (8 courses of 10 days each)
Number of subjects: 195
Study 39687431 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (S-arm)
Number of subjects: 195
Study 39687431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 195
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index
Number of subjects: 2726
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index in FLI <30
Number of subjects: 2726
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index in FLI 30-60
Number of subjects: 2726
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index in FLI ≥60
Number of subjects: 2726
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction term for FIB-4 index with FLI ≥60 (reference FLI <30)
Number of subjects: 2726
Study 39687670 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable linear regressions
Number of subjects: 2726
Study 39687787 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 1490
Study 39687787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1490
Study 39688344 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-field confocal optical coherence tomography (LC-OCT) combined with artificial intelligence (AI) algorithms
Number of subjects: 0
Study 39688344 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39688408 — intervention group
Group type: EXPERIMENTAL
Intervention: Leritrelvir 400 mg
Number of subjects: 24
Study 39688775 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G system
Number of subjects: 270
Study 39688776 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 111
Study 39688866 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tai ji quan
Number of subjects: 318
Study 39688866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively enhanced tai ji quan
Number of subjects: 318
Study 39688866 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 318
Study 39689129 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus STRATIFY intervention (web-based algorithm for risk stratification and matched interventions)
Number of subjects: 0
Study 39689129 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39689146 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention (six-month intervention including six monthly hypertension educational sessions, monthly blood pressure monitoring, follow up care coordination, fully subsidized antihypertensive medications, standardized treatment algorithm, training for providers)
Number of subjects: 100
Study 39689146 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH intervention
Number of subjects: 100
Study 39689189 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase
Number of subjects: 390
Study 39689189 — intervention group
Group type: COMPARATOR
Intervention: Full-dose tenecteplase
Number of subjects: 390
Study 39689189 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 390
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined native tissue vaginal prolapse repair with midurethral sling
Number of subjects: 254
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpocleisis (as a protective factor)
Number of subjects: 254
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 254
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic stress urinary incontinence (SUI)
Number of subjects: 254
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 254
Study 39689213 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 254
Study 39689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear imaging (n=1532)
Number of subjects: 3601
Study 39689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (n=827)
Number of subjects: 3601
Study 39689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (n=108)
Number of subjects: 3601
Study 39689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise tolerance test (n=1134)
Number of subjects: 3601
Study 39689295 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning high-intensity interval exercise (HIIE)
Number of subjects: 26
Study 39689295 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening high-intensity interval exercise (HIIE)
Number of subjects: 26
Study 39689295 — intervention group
Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 26
Study 39689939 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week home-based pulmonary rehabilitation (PR)
Number of subjects: 50
Study 39689939 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 50
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 5 mm to 8 mm for 'MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 8 mm to 10 mm for 'MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 5 mm to 7 mm for 'MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 5 mm to 8 mm for 'AAH+AIS+MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 5 mm to 7 mm for 'IA-only'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 7 mm to 10 mm for 'MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 7 mm to 10 mm for 'AAH+AIS+MIA+IA'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 7 mm to 10 mm for 'IA-only'
Number of subjects: 0
Study 39689940 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 8 mm predictive model
Number of subjects: 0
Study 39689944 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically heated mittens worn for at least 15 minutes daily for six weeks
Number of subjects: 200
Study 39689944 — intervention group
Group type: COMPARATOR
Intervention: Control mittens (heating elements disconnected) worn for at least 15 minutes daily for six weeks
Number of subjects: 200
Study 39689992 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted microwave ablation (TMA)
Number of subjects: 30
Study 39690158 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezvilutamide plus androgen deprivation therapy (REZ-ADT)
Number of subjects: 0
Study 39690339 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Diverters (FDs)
Number of subjects: 152
Study 39690339 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent-assisted coiling
Number of subjects: 152
Study 39690977 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral by primary care clinicians (PCCs)
Number of subjects: 5322
Study 39690977 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred patients
Number of subjects: 5322
Study 39691038 — intervention group
Group type: EXPERIMENTAL
Intervention: Genoss DES
Number of subjects: 483
Study 39691038 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 483
Study 39691073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular comorbidities (hypertension)
Number of subjects: 445
Study 39691073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular comorbidities (hyperlipidaemia)
Number of subjects: 445
Study 39691073 — intervention group
Group type: EXPERIMENTAL
Intervention: Having ≥2 comorbidities
Number of subjects: 445
Study 39691073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular comorbidities/comorbidity count
Number of subjects: 445
Study 39691073 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comorbidity burden
Number of subjects: 445
Study 39691156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate
Number of subjects: 0
Study 39691156 — intervention group
Group type: COMPARATOR
Intervention: Dual Therapies
Number of subjects: 0
Study 39691173 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intra-articular injections, oral opioid and nonopioid medications (including nonsteroidal anti-inflammatory drugs), cryo nerve blocks, radiofrequency ablations, novel treatment modalities, other physical therapy modalities (including muscle strengthening), and total knee arthroplasties.
Number of subjects: 0
Study 39691173 — intervention group
Group type: EXPERIMENTAL
Intervention: Index joint-directed treatments
Number of subjects: 0
Study 39691275 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-CLL17 domain scores assessment
Number of subjects: 62
Study 39691290 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment
Number of subjects: 402
Study 39691584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educator led ART refill model
Number of subjects: 123
Study 39691584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer educator led Saturday clinic club for ART collection
Number of subjects: 123
Study 39691584 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders for treatment adherence and ART refill visits
Number of subjects: 123
Study 39691584 — intervention group
Group type: EXPERIMENTAL
Intervention: Support by peer educator
Number of subjects: 123
Study 39691584 — intervention group
Group type: EXPERIMENTAL
Intervention: Support by nurse without peer educator involvement
Number of subjects: 123
Study 39691654 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest ultrasound (CUS)
Number of subjects: 136
Study 39691654 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 136
Study 39691654 — intervention group
Group type: COMPARATOR
Intervention: Computer-aided diagnosis (CAD)
Number of subjects: 136
Study 39691721 — intervention group
Group type: EXPERIMENTAL
Intervention: scRNA-seq analysis on peripheral blood lymphocytes
Number of subjects: 20
Study 39691721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent spot (ELISpot), cytokine production analysis, and T-cell proliferation assays
Number of subjects: 20
Study 39691748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% white hydrogel plasters
Number of subjects: 180
Study 39691748 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (plain hydrogel plasters)
Number of subjects: 180
Study 39691747 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping plus standard analgesic treatment
Number of subjects: 34
Study 39691747 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment
Number of subjects: 34
Study 39691834 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence of Medicine (AIMED) system using convolutional neural networks and MobileNetV3-large
Number of subjects: 16031
Study 39692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 4 mg/kg (maximum 400 mg), single cycle
Number of subjects: 42
Study 39692004 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after pembrolizumab treatment
Number of subjects: 42
Study 39692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PlGF
Number of subjects: 370
Study 39692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FW
Number of subjects: 370
Study 39692213 — intervention group
Group type: EXPERIMENTAL
Intervention: FW
Number of subjects: 370
Study 39692262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)-based mobile application
Number of subjects: 91
Study 39692262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 39692276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercises with physiotherapist in primary care twice a week for 12 weeks and daily walks
Number of subjects: 90
Study 39692276 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home-based exercise including daily walks
Number of subjects: 90
Study 39692401 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 504
Study 39692552 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aerobic exercise treatment
Number of subjects: 56
Study 39692702 — intervention group
Group type: EXPERIMENTAL
Intervention: STP705
Number of subjects: 8
Study 39692702 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 39692742 — intervention group
Group type: EXPERIMENTAL
Intervention: Stump length measurement
Number of subjects: 16
Study 39692742 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Number of subjects: 16
Study 39692742 — intervention group
Group type: EXPERIMENTAL
Intervention: Other muscle strength and proprioception parameters
Number of subjects: 16
Study 39692817 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 39692817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39692838 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgency Numeric Rating Scale (NRS)
Number of subjects: 0
Study 39692838 — intervention group
Group type: COMPARATOR
Intervention: Patient Global Rating of Severity (PGRS)
Number of subjects: 0
Study 39692838 — intervention group
Group type: COMPARATOR
Intervention: Patient Global Impression of Change (PGIC)
Number of subjects: 0
Study 39693081 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole + Sertraline
Number of subjects: 416
Study 39693081 — intervention group
Group type: COMPARATOR
Intervention: Sertraline + Placebo
Number of subjects: 416
Study 39693096 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3) (6 mmol 3 times daily)
Number of subjects: 84
Study 39693096 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3)
Number of subjects: 84
Study 39693096 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride (KCl)
Number of subjects: 84
Study 39693097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided online CBT intervention for 12 weeks
Number of subjects: 168
Study 39693097 — intervention group
Group type: COMPARATOR
Intervention: Clinician-guided online CBT for 12 weeks
Number of subjects: 168
Study 39693139 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS)-based intervention
Number of subjects: 2501
Study 39693139 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention (health insurance representative visit with feedback)
Number of subjects: 2501
Study 39693139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2501
Study 39693227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 300 mg for weight >40 kg, 5 mg/kg for weight ≤40 kg every 4 weeks during induction; subcutaneous mirikizumab 200 mg (>40 kg), 100 mg (>20 to ≤40 kg), or 50 mg (≤20 kg) every 4 weeks during maintenance therapy.
Number of subjects: 26
Study 39693244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (positive control)
Number of subjects: 36
Study 39693244 — intervention group
Group type: COMPARATOR
Intervention: Antagonists blocking TRPA1, TRPM8, NaV1.7, and NaV1.8
Number of subjects: 36
Study 39693244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of TRPA1, TRPM8, and NaV1.7
Number of subjects: 36
Study 39693244 — intervention group
Group type: EXPERIMENTAL
Intervention: NaV1.8 inhibition
Number of subjects: 36
Study 39693245 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) for 6 months
Number of subjects: 47
Study 39693261 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier physical therapy (started within 1 week)
Number of subjects: 203
Study 39693261 — intervention group
Group type: COMPARATOR
Intervention: Later physical therapy (started after 6 weeks)
Number of subjects: 203
Study 39693261 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier physical therapy
Number of subjects: 203
Study 39693261 — intervention group
Group type: COMPARATOR
Intervention: Later physical therapy
Number of subjects: 203
Study 39693517 — intervention group
Group type: COMPARATOR
Intervention: ATRA/chemotherapy
Number of subjects: 647
Study 39693517 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA/i.v.-ATO
Number of subjects: 647
Study 39693517 — intervention group
Group type: EXPERIMENTAL
Intervention: oral-AAA (ATRA/oral-ATO/ascorbic acid with ATO maintenance)
Number of subjects: 647
Study 39693517 — intervention group
Group type: COMPARATOR
Intervention: ATRA/chemotherapy/non-ATO maintenance
Number of subjects: 647
Study 39693517 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA/chemotherapy/ATO maintenance
Number of subjects: 647
Study 39693517 — intervention group
Group type: EXPERIMENTAL
Intervention: oral-AAA
Number of subjects: 647
Study 39693611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemin or protoporphyrin IX supplementation
Number of subjects: 0
Study 39693611 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting ferrochetalase
Number of subjects: 0
Study 39693611 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-targeting BCL-2 and MCL-1
Number of subjects: 0
Study 39693611 — intervention group
Group type: COMPARATOR
Intervention: Increased purine and pyrimidine biosynthesis
Number of subjects: 0
Study 39693611 — intervention group
Group type: COMPARATOR
Intervention: Elevated heme and purine biosynthesis gene signatures
Number of subjects: 0
Study 39693720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of oestrone
Number of subjects: 5535
Study 39693720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of testosterone
Number of subjects: 5535
Study 39693720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile concentrations of dehydroepiandrosterone
Number of subjects: 5535
Study 39693827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 126
Study 39693827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 39694040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic fasting-mimicking diet (FMD) regimen, triweekly, 5-day
Number of subjects: 30
Study 39694102 — intervention group
Group type: EXPERIMENTAL
Intervention: High neighborhood SES (ADI categorized as highest 15%)
Number of subjects: 615